Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02029443 · ClinicalTrials.gov registry record · Phase 1

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

A Phase 1 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Acerta Pharma.

Active
Registry status
Phase 1
Development phase
306
Enrollment target
12
Study locations

NCT02029443 is a Phase 1 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma that is active but no longer recruiting, run by Acerta Pharma. The registered enrollment target is 306 participants, above the 180-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (70% higher). The trial reports 12 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02029443, a Phase 1 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, is active but no longer recruiting, sponsored by Acerta Pharma.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
306 participants
Enrollment target
12
Study locations

Study Summary

This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Conditions Studied

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Prolymphocytic Leukemia Richter's Syndrome

Interventions

  • DRUG Acalabrutinib

Study Locations (12)

Other

  • Research Site - Milan
  • Research Site - Leeds
  • Research Site - London
  • Research Site - Oxford

New York

  • Research Site - New Hyde Park
  • Research Site - New York

Washington

  • Research Site - Seattle
  • Research Site - Tacoma

Massachusetts

  • Research Site - Boston

Ohio

  • Research Site - Columbus

Texas

  • Research Site - Fort Worth

Utah

  • Research Site - Salt Lake City

Trial Details

FieldValue
Enrollment Target 306 participants
Start Date 2014-01-30
Est. Completion 2027-06-09
Phase Phase 1

Sponsor

Acerta Pharma

38 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02029443

The ClinicalTrials.gov registry entry for NCT02029443 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 306 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 180-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (70% higher). The listed sponsor is Acerta Pharma, which has 38 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Acalabrutinib is the first listed.

NCT02029443 reports 12 study locations spanning 7 distinct geographic areas - top geographies include Other, New York, Washington.

Frequently Asked Questions

What is clinical trial NCT02029443 about?

NCT02029443 is a clinical study titled "ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia". This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

What is the current status of trial NCT02029443?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 306 participants. The study started on 2014-01-30. Estimated completion is 2027-06-09.

What conditions does trial NCT02029443 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, Richter's Syndrome.

What interventions are being tested in trial NCT02029443?

The interventions under investigation include: Acalabrutinib (DRUG).

Who is sponsoring clinical trial NCT02029443?

This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02029443 being conducted?

This trial has 12 study locations across Massachusetts, New York, Ohio, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Lymphocytic Leukemia

All registered trials for this condition

Small Lymphocytic Lymphoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.